Miller M A
Division of Infectious Diseases, Department of Microbiology, Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote-Ste-Catherine, Montreal, Quebec, Canada.
Postgrad Med. 2001 Feb;109(2 Suppl):39-42. doi: 10.3810/pgm.02.2001.suppl12.64.
The incidence of Clostridium difficile-associated disease (CDAD) has increased significantly since it was first recognized in the 1970s. CDAD can occur in the outpatient setting, but most cases are nosocomial. The symptoms range from mild diarrhea to severe colitis, and although diarrhea is often considered a nuisance, CDAD is associated with significant morbidity, mortality, and human costs. Control of CDAD is a challenge for many healthcare facilities. In addition to limiting the transmission of C difficile by such measures as patient isolation, careful hand-washing, environmental disinfection, and barrier precautions, many institutions are focusing on antibiotic manipulation and biotherapy. Among the suggestions for antibiotic manipulation are decreased overall use of antibiotics and use of lower-risk antibiotics such as penicillins instead of high-risk antibiotics such as clindamycin and cephalosporins.
自20世纪70年代首次被发现以来,艰难梭菌相关疾病(CDAD)的发病率显著上升。CDAD可发生在门诊环境中,但大多数病例为医院获得性感染。症状从轻度腹泻到严重结肠炎不等,尽管腹泻通常被认为是个麻烦事,但CDAD会导致显著的发病率、死亡率和人力成本。对许多医疗机构来说,控制CDAD是一项挑战。除了通过患者隔离、仔细洗手、环境消毒和屏障预防措施等手段限制艰难梭菌的传播外,许多机构还专注于抗生素管理和生物疗法。抗生素管理的建议包括减少抗生素的总体使用,以及使用低风险抗生素如青霉素,而不是高风险抗生素如克林霉素和头孢菌素。